CA2162921A1 - Derives du carbazole avec activite inhibitrice de la 17,20-lyase - Google Patents
Derives du carbazole avec activite inhibitrice de la 17,20-lyaseInfo
- Publication number
- CA2162921A1 CA2162921A1 CA002162921A CA2162921A CA2162921A1 CA 2162921 A1 CA2162921 A1 CA 2162921A1 CA 002162921 A CA002162921 A CA 002162921A CA 2162921 A CA2162921 A CA 2162921A CA 2162921 A1 CA2162921 A1 CA 2162921A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- group
- carbazole
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
L'invention se rapporte à des dérivés de carbazole substitués, à des procédés destinés à leur préparation, à des compositions pharmaceutiques les contenant ainsi qu'à leur utilisation à des fins médicales pour la réduction des niveaux d'oestrogènes et/ou d'androgènes. L'invention concerne particulièrement des composés de la formule (I), dans laquelle R1 et R4 représentent chacun indépendamment un atome d'hydrogène ou un groupe C1-6 alkyle; tous les R2 peuvent être identiques ou différents et représentent un groupe d'enlèvement d'électrons; tous les R3 peuvent être identiques ou différents et représentent un groupe d'enlèvement d'électrons; R5 représente un groupe de la formule (a), (b) ou (c); R6 représente un atome d'halogène, un groupe C1-6 alkyle ou un groupe C1-6 alcoxy; m vaut zéro ou un entier de 1 à 4; n vaut zéro ou un entier de 1 à 3; et p vaut zéro, 1 ou 2. Des solvants et sels pharmaceutiquement acceptables de ces composés sont également décrits.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9310635.9 | 1993-05-21 | ||
GB939310635A GB9310635D0 (en) | 1993-05-21 | 1993-05-21 | Chemical compounds |
PCT/EP1994/001613 WO1994027989A1 (fr) | 1993-05-21 | 1994-05-19 | Derives de carbazole a activite d'inhibition de 17,20-lyase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2162921A1 true CA2162921A1 (fr) | 1994-12-08 |
Family
ID=10736007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002162921A Abandoned CA2162921A1 (fr) | 1993-05-21 | 1994-05-19 | Derives du carbazole avec activite inhibitrice de la 17,20-lyase |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0699196A1 (fr) |
JP (1) | JPH08510455A (fr) |
CN (1) | CN1126473A (fr) |
AU (1) | AU6928794A (fr) |
BG (1) | BG100154A (fr) |
CA (1) | CA2162921A1 (fr) |
CZ (1) | CZ305195A3 (fr) |
FI (1) | FI955587A (fr) |
GB (1) | GB9310635D0 (fr) |
HU (1) | HUT73790A (fr) |
IL (1) | IL109703A0 (fr) |
NO (1) | NO954681D0 (fr) |
OA (1) | OA10195A (fr) |
PE (1) | PE31195A1 (fr) |
PL (1) | PL311702A1 (fr) |
SK (1) | SK142495A3 (fr) |
TW (1) | TW279866B (fr) |
WO (1) | WO1994027989A1 (fr) |
ZA (1) | ZA943494B (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009157A1 (fr) * | 1993-09-30 | 1995-04-06 | Yamanouchi Pharmaceutical Co., Ltd. | Derive d'azole et composition pharmaceutique le contenant |
AU3846395A (en) * | 1994-11-07 | 1996-05-31 | Janssen Pharmaceutica N.V. | Compositions comprising carbazoles and cyclodextrins |
AU702406B2 (en) * | 1995-03-01 | 1999-02-18 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazole derivatives and medicinal composition thereof |
AU6229698A (en) * | 1997-02-21 | 1998-09-09 | Takeda Chemical Industries Ltd. | Fused ring compounds, process for producing the same and use thereof |
KR100725442B1 (ko) | 2000-11-17 | 2007-06-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 신규 이미다졸 유도체, 이의 제조 방법 및 이의 용도 |
AU2002214320A1 (en) | 2000-11-20 | 2002-05-27 | Takeda Chemical Industries Ltd. | Imidazole derivatives, process for their preparation and their use |
AU2002221080A1 (en) | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
CN101203491A (zh) | 2005-06-24 | 2008-06-18 | 伊莱利利公司 | 可用作雄激素受体调节剂的四氢咔唑衍生物(sarm) |
GB0525323D0 (en) * | 2005-12-13 | 2006-01-18 | Sterix Ltd | Compound |
US8093279B2 (en) | 2005-12-13 | 2012-01-10 | Gillian Reed, legal representative | Compound |
CN100586932C (zh) * | 2007-01-26 | 2010-02-03 | 中国医学科学院医药生物技术研究所 | 抗肿瘤化合物及其制备方法 |
MY155570A (en) | 2009-06-26 | 2015-10-30 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
EP2531029B1 (fr) * | 2010-02-04 | 2016-10-19 | Radius Health, Inc. | Modulateurs sélectifs du récepteur des androgènes |
WO2011143469A1 (fr) | 2010-05-12 | 2011-11-17 | Radius Health,Inc | Schémas thérapeutiques |
WO2012018948A2 (fr) | 2010-08-04 | 2012-02-09 | Pellficure Pharmaceuticals, Inc. | Nouveau traitement du carcinome de la prostate |
WO2012035078A1 (fr) | 2010-09-16 | 2012-03-22 | Novartis Ag | Inhibiteurs de la 17α-hydroxylase/c17,20-lyase |
WO2012047617A1 (fr) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Modulateurs sélectifs du récepteur des androgènes |
EP2702052B1 (fr) | 2011-04-28 | 2017-10-18 | Novartis AG | Inhibiteurs de 17a-hydroxylase/c17,20-lyase |
US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
US20160022606A1 (en) | 2013-03-14 | 2016-01-28 | Pellficure Pharmaceuticals Inc. | Novel therapy for prostate carcinoma |
EP3834824A1 (fr) | 2014-03-28 | 2021-06-16 | Duke University | Méthode de traitement du cancer faisant intervenir des modulateurs sélectifs des récepteurs des strogènes |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
US10093620B2 (en) | 2014-09-12 | 2018-10-09 | Pellficure Pharmaceuticals, Inc. | Compositions and methods for treatment of prostate carcinoma |
WO2017223115A1 (fr) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Méthodes ar+ de traitement du cancer du sein |
EP3528799A1 (fr) | 2016-10-24 | 2019-08-28 | Pellficure Pharmaceuticals, Inc. | Compositions pharmaceutiques de 5-hydroxy-2-méthylnaphtalène-1, 4-dione |
JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形性形態 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CS229934B2 (en) * | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
GB8518743D0 (en) * | 1985-07-24 | 1985-08-29 | Glaxo Group Ltd | Heterocyclic compounds |
-
1993
- 1993-05-21 GB GB939310635A patent/GB9310635D0/en active Pending
-
1994
- 1994-05-02 ZA ZA943494A patent/ZA943494B/xx unknown
- 1994-05-17 TW TW083104441A patent/TW279866B/zh active
- 1994-05-19 WO PCT/EP1994/001613 patent/WO1994027989A1/fr not_active Application Discontinuation
- 1994-05-19 JP JP7500181A patent/JPH08510455A/ja active Pending
- 1994-05-19 HU HU9503321A patent/HUT73790A/hu unknown
- 1994-05-19 CN CN94192683A patent/CN1126473A/zh active Pending
- 1994-05-19 AU AU69287/94A patent/AU6928794A/en not_active Abandoned
- 1994-05-19 PL PL94311702A patent/PL311702A1/xx unknown
- 1994-05-19 CA CA002162921A patent/CA2162921A1/fr not_active Abandoned
- 1994-05-19 CZ CZ953051A patent/CZ305195A3/cs unknown
- 1994-05-19 SK SK1424-95A patent/SK142495A3/sk unknown
- 1994-05-19 EP EP94917647A patent/EP0699196A1/fr not_active Withdrawn
- 1994-05-20 IL IL10970394A patent/IL109703A0/xx unknown
- 1994-11-18 PE PE1994255110A patent/PE31195A1/es not_active Application Discontinuation
-
1995
- 1995-11-17 OA OA60742A patent/OA10195A/en unknown
- 1995-11-20 NO NO954681A patent/NO954681D0/no unknown
- 1995-11-20 FI FI955587A patent/FI955587A/fi not_active Application Discontinuation
- 1995-11-21 BG BG100154A patent/BG100154A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0699196A1 (fr) | 1996-03-06 |
CN1126473A (zh) | 1996-07-10 |
HUT73790A (en) | 1996-09-30 |
PE31195A1 (es) | 1995-10-18 |
CZ305195A3 (en) | 1996-06-12 |
FI955587A0 (fi) | 1995-11-20 |
IL109703A0 (en) | 1994-08-26 |
HU9503321D0 (en) | 1996-01-29 |
NO954681L (no) | 1995-11-20 |
BG100154A (en) | 1996-07-31 |
WO1994027989A1 (fr) | 1994-12-08 |
AU6928794A (en) | 1994-12-20 |
TW279866B (fr) | 1996-07-01 |
GB9310635D0 (en) | 1993-07-07 |
NO954681D0 (no) | 1995-11-20 |
JPH08510455A (ja) | 1996-11-05 |
OA10195A (en) | 1996-12-18 |
SK142495A3 (en) | 1996-06-05 |
PL311702A1 (en) | 1996-03-04 |
ZA943494B (en) | 1995-01-23 |
FI955587A (fi) | 1995-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2162921A1 (fr) | Derives du carbazole avec activite inhibitrice de la 17,20-lyase | |
AU654350B2 (en) | Benzofuran derivatives | |
EP3064498B1 (fr) | Dérivés pyrazolopyrimidone ou pyrrolotriazone, leur procédé de préparation, et applications pharmaceutiques associées | |
IE904146A1 (en) | Indole Derivatives | |
JPH05501566A (ja) | 3―置換―1―(アリールまたはアリールアルキル)―2(1h)―キノリノン | |
WO2000066574A1 (fr) | 2,1-benzisothiazoline 2,2-dioxydes | |
JP2707936B2 (ja) | β−オキソ−β−ベンゼンプロパンチオアミド誘導体 | |
CA2214744C (fr) | Derives de 3-(bis-phenylmethylene substitue) oxindole | |
US5578630A (en) | Heterocyclic compounds which inhibit aromatase | |
US6689798B2 (en) | Benzofuran derivatives | |
US10214496B2 (en) | Azasteroidal mimics | |
JP2008513422A (ja) | インドリン−2−オンピリジン誘導体、その調製及び治療上の使用 | |
US5726196A (en) | Aromatase-inhibiting composition containing azole derivative | |
KR102406248B1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 | |
KR102406246B1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
EP0574992A1 (fr) | Dérivés de 5(1,2,4-triazol-1-ylméthyl)-3H-isobenzofuran-1-one, leurs préparation et application en tant qu'inhibiteurs d'aromatase | |
JPS6256471A (ja) | 含窒素四環式化合物 | |
KR101637416B1 (ko) | 구굴스테론 유도체, 그 제조방법 및 그를 포함하는 조성물 | |
HUT59107A (en) | Process for producing new 4(5)-imidazole derivatives having aromatase inhibiting activity and pharmaceutical compositions comprising same as active ingredient | |
SK286757B6 (sk) | 17-Metylénsteroidy, spôsob ich prípravy, farmaceutické kompozície, ktoré ich obsahujú, a ich použitie | |
JPS633859B2 (fr) | ||
MXPA98004819A (en) | Gonadotrop liberating hormone antagonists | |
EP1175413A1 (fr) | 2,1-benzisothiazoline 2,2-dioxydes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |